About BioStem Technologies
BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local MicroEnvironment Activation, or LMA, uses combinations of Small Molecules, Cytokines, and Growth Factors (“SMCGF”) to activate the microenvironment within the body to create communication for repair in the tissue.
Since our founding in 2014, we’ve pursued a singular goal: growing into an innovative life sciences company with the power to change lives for the better. BioStem Technologies is a leading manufacturer and distributor of superior perinatal tissue allografts for use in regenerative therapies. Our team has extensive scientific, medical and technical expertise in birth tissue processing for biologic products.
In 2015 we founded our own 6000 square foot lab and manufacturing facility in Pompano Beach, Fl., doing business as BioStem Life Sciences.
Over 10,000 procedures have been conducted using BioStem products, with zero reported adverse events. Through our rigorous quality and proprietary production processes, we demonstrate our commitment to excellence and our focus on patient safety.Learn About Our Products
We exceed the highest quality standards, ensuring our products more than meet industry standard specifications.
Our motto, "Science With Humanity" is more than just a clever saying, it's how we govern our practices.
By developing novel approaches to industry changing processes, we focus on better than status quo.
What is Regenerative Medicine?
Soft tissue damage through disease and injury has catapulted the development of specialized therapies that can regenerate these tissues and decrease the reliance on limited steroidal treatments or addictive opioid prescriptions for pain. Regenerative medicine, on the whole, is an interdisciplinary field that applies engineering and life science principles to promote this regeneration with the hope of restoring the diseased or injured tissues.Get More Information
Using Perinatal Tissue In Regenerative Therapies
The first reported clinical use of perinatal-derived tissue allografts for aiding in wound healing was at Johns Hopkins over a century ago in 1910. In recent years, both clinical and research applications of these biomaterials have increased in scope to include roles in tissue engineering and regenerative medicine. Perinatal tissues are an abundant source of extracellular matrix components and growth factors, with potential use in a broad array of regenerative therapies. These components have translated well to regenerative applications owing to their low immunogenicity, positive wound healing characteristics, and minimal tissue inflammation1-2. The two most widely adopted perinatal components for clinical use are the umbilical cord and the amniotic membrane.Learn About Perinatal Tissue Components
1. Fukuchi, Y., Nakajima, H., Sugiyama, D., Hirose, I., Kitamura, T. and Tsuji, K. (2004), Human Placenta‐Derived Cells Have Mesenchymal Stem/Progenitor Cell Potential. STEM CELLS, 22: 649-658. doi:10.1634/stemcells.22-5-649
2. W.Page Faulk, PeterJ Stevens, Hugo Burgos, Richard Matthews, JohnP Bennett, Bae-Li Hsi, HUMAN AMNION AS AN ADJUNCT IN WOUND HEALING, The Lancet, Volume 315, Issue 8179,1980, Pages 1156-1158, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(80)91617-7